KR20240168923A - 항-c5 항체 크로발리맙을 사용하여 길랭-바레 증후군을 치료 또는 예방하기 위한 투여량 및 투여 요법 - Google Patents

항-c5 항체 크로발리맙을 사용하여 길랭-바레 증후군을 치료 또는 예방하기 위한 투여량 및 투여 요법 Download PDF

Info

Publication number
KR20240168923A
KR20240168923A KR1020247025239A KR20247025239A KR20240168923A KR 20240168923 A KR20240168923 A KR 20240168923A KR 1020247025239 A KR1020247025239 A KR 1020247025239A KR 20247025239 A KR20247025239 A KR 20247025239A KR 20240168923 A KR20240168923 A KR 20240168923A
Authority
KR
South Korea
Prior art keywords
antibody
subject
ivig
dose
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247025239A
Other languages
English (en)
Korean (ko)
Inventor
사이먼 베르트랑 마리 부아토이스
게이스케 고탄다
겐지 시노미야
알렉상드르 앙투안 베르나르 소스텔리
앙투안 폴 막상스 수브레
Original Assignee
에프. 호프만-라 로슈 아게
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게, 추가이 세이야쿠 가부시키가이샤 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20240168923A publication Critical patent/KR20240168923A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020247025239A 2022-04-04 2023-04-03 항-c5 항체 크로발리맙을 사용하여 길랭-바레 증후군을 치료 또는 예방하기 위한 투여량 및 투여 요법 Pending KR20240168923A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166586 2022-04-04
EP22166586.2 2022-04-04
PCT/EP2023/058605 WO2023194271A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
KR20240168923A true KR20240168923A (ko) 2024-12-02

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025239A Pending KR20240168923A (ko) 2022-04-04 2023-04-03 항-c5 항체 크로발리맙을 사용하여 길랭-바레 증후군을 치료 또는 예방하기 위한 투여량 및 투여 요법

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20230303670A1 (en) * 2020-06-24 2023-09-28 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Also Published As

Publication number Publication date
MX2024009673A (es) 2024-09-11
JP2025510490A (ja) 2025-04-15
AU2023248634A1 (en) 2024-05-16
CA3251879A1 (en) 2023-10-12
US20250236661A1 (en) 2025-07-24
EP4504773A1 (en) 2025-02-12
IL313962A (en) 2024-08-01
TW202346339A (zh) 2023-12-01
WO2023194271A1 (en) 2023-10-12
CN118556078A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
JP7663559B2 (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
KR20250107839A (ko) 심혈관계 질환의 치료 방법
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
KR20240168923A (ko) 항-c5 항체 크로발리맙을 사용하여 길랭-바레 증후군을 치료 또는 예방하기 위한 투여량 및 투여 요법
KR20240168984A (ko) 항-c5 항체 크로발리맙을 이용하는 길랭 바레 증후군의 치료 또는 예방을 위한 용량 및 투여 요법
CN104395343A (zh) 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案
WO2017120261A1 (en) Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
US20260097063A1 (en) Anti-c5 antibody/c5 irna dosing regimens for treating c5-associated diseases
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
WO2025096435A1 (en) Treatment of complement-associated renal diseases
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
EP4731680A1 (en) Methods of administering fviii mimetic bispecific antibodies once every second month

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000